족부백선 치료에서 Terbinafine과 Itraconazole의 비교 임상연구 = Clinical Comparative Study of Terbinafine and Itraconazole in the Treatment of Tinea Pedis

다국어 초록 (Multilingual Abstract)

With the objective of assessing efficacy and safety, sixty patients (30 in each group) with clinically and mycologically confirmed tinea pedis were randomised in a single-blind fashion to receive either 250㎎ orally once daily Terbinafine(Lamisil®) for 2 weeks or 100㎎ orally once daily ltraconazole(Sproanox®) for 4 weeks, Terbinafine is an allylamine, fungicidal antimycotic agent, while Itraconazole is an anti-fungal of triazole series.
The patients were well matched for age, clinical features and type of dermatophytes.
Clinical response was measured by scoring system(0?3) at weekly intervals for 4 weeks, while tolerability (on a scale of 1-5), adverse events and liver biochemistry were assenssed every 2 weeks. Any variance compared to the base-line was recorded by the repeated measure analysis of Variance(Anova) and Wilcoxoson test.
At 4 weeks, clinical respose mean of seven scores changed from 1.23±0.85 to 0.27±0.34 for Terbinafine (P<0.05) and from 1.46±0.85 to 0.36±0.39 for Itraconazole (P<0.05). Both drugs are effective, however, there is no significant difference of the relative effectiveness of both drugs at 4 weeks.
The overall tolerability scores for Terbinafine were significantly lower compared to Itraconazole (P<0.05).
In conclusion, it may be suggested that both drugs are equally effective in the treatment of Tinea pedis; however, Terbinafine proves to be better in terms of better tolerability and shorter duration of treatment(2 weeks vs 4 weeks).